The Effects of Saffron ( Crocus Sativus L ) Supplementation on Cardiovascular Risk Factors, Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Double-blind, Placebo-controlled Study
Reyhane Sadat Mirnasrollahi Parsa,Naheed Aryaeian,Marjan mokhtare,Farnaz kavianipour,Leila Janani,Shahram Agah,Nariman Moradi
DOI: https://doi.org/10.1016/j.hermed.2024.100877
IF: 2.542
2024-04-01
Journal of Herbal Medicine
Abstract:introduction This study was designed to investigate the effects of Saffron supplementation on liver FibroScan test, liver enzymes, lipid profile, total and direct bilirubin, glycemic profile, and blood pressure in nonalcoholic fatty liver disease (NAFLD) patients. The researchers hypothesized that supplementation with Saffron could further improve the efficacy of lifestyle modifications in managing NAFLD. Methods This randomized, double-blind, placebo-controlled trial was conducted on 76 NAFLD patients, whose age range was from 18 to 65. All of them were given a specified weight loss diet and a physical activity program. They were randomly assigned into two groups to intake 100 mg of a Saffron-coated tablet (n=38) or a placebo tablet (n=38) for 12 weeks. Liver FibroScan test, liver enzymes (as primary outcome), lipid profile, total and direct bilirubin, fasting blood sugar (FBS), insulin, insulin resistance (HOMA-IR), insulin sensitivity (QUICKI), blood pressure, dietary intake, and physical activity were measured at baseline and also after 12 weeks. Both the participants and the dietitians were blindly assigned to the groups. Statistical analysis was carried out using SPSS software version 22. Results Finally, 36 patients completed the study, and 38 patients were included in the intention-to-treat analysis. Accordingly, Saffron supplementation reduced steatosis score (P > 0.001), steatosis percent (P > 0.001) and steatosis stage (P > 0.001), total cholesterol (TC) (P = 0.001), triacylglycerol (TG) (P > 0.001), LDL-C (P = 0.005), and FBS (P = 0.009) more than placebo. There was no significant difference in liver fibrosis, ALT (-1.33 IU/L, 95% CI= -5.10, 2.43, P = 0.482), AST (-0.20 IU/L, 95% CI= -2.94, 2.52, P = 0.880), GGT, insulin, HOMA-IR, and QUICKI indexes, total and direct bilirubin, and blood pressure between the two groups (P > 0.05). Conclusions Overall, the 12-week consumption of 100 mg Saffron, along with lifestyle modification, compared with placebo, had insignificant reducing effects on liver steatosis score, steatosis percent, and steatosis stage, total cholesterol, TG, LDL-C, and FBS among NAFLD patients. Saffron may exert considerable beneficial consequences that need further assessment in future clinical trials.
integrative & complementary medicine